Stüve–Wiedemann Syndrome 1: Disease-Characteristics Research Report

Executive summary and scope

Stüve–Wiedemann syndrome (SWS) is a congenital, usually severe autosomal-recessive bent-bone skeletal dysplasia with dysautonomia, most often caused by biallelic loss-of-function variants in LIFR. The early phenotype combines bowed long bones and contractures with respiratory distress, dysphagia/aspiration, temperature instability, abnormal sweating, and reduced pain sensation. Survivors experience decreasing dysautonomic severity but increasing orthopedic morbidity. In the best available systematic review (69 patients), mortality was 42% before age 2, compared with 10% after age 2; pulmonary arterial hypertension (PAH) was associated with 63% mortality. After age 2, restricted joint mobility, spinal deformity, and fractures were reported in 81%, 77%, and 61%, respectively. These estimates come from published cases and are vulnerable to ascertainment and survival bias. (warnier2022clinicaloverviewand pages 1-3, warnier2022clinicaloverviewand pages 10-11)

Curation warning: “Stüve–Wiedemann syndrome 1” should denote classic LIFR-related SWS. Biallelic complete loss of IL6ST/GP130 causes a related but broader entity termed extended Stüve–Wiedemann syndrome, with additional immune, hematologic, renal, and cutaneous manifestations. It should not be merged uncritically with classic SWS1. (chen2020absenceofgp130 pages 8-9, chen2020absenceofgp130 pages 1-1)

The compact knowledge-base summary below complements the narrative report.

Table: This table condenses the main disease-knowledge-base fields for classic LIFR-related Stüve-Wiedemann syndrome, including identity, genetics, phenotype, mechanism, diagnosis, prognosis, treatment, prevention, and model evidence. It also flags key curation issues such as OMIM ambiguity and the need to distinguish classic SWS1 from IL6ST-related extended SWS.

1. Disease information

Definition

Classic SWS is an inherited osteochondrodysplasia characterized radiographically by congenital bowing of long bones, cortical thickening, widened/flared metaphyses with abnormal trabeculation or reduced density, and clinically by contractures plus severe neonatal autonomic and respiratory dysfunction. The syndrome historically overlapped with “Schwartz–Jampel syndrome type 2”; molecular work established these as the same LIFR-null disorder rather than distinct diseases. (bertola2016stüvewiedemannsyndromeupdate pages 1-2, bertola2016stüvewiedemannsyndromeupdate pages 5-6, warnier2022clinicaloverviewand pages 1-3)

Identifiers and synonyms

• Preferred name: Stüve–Wiedemann syndrome; often written Stuve-Wiedemann syndrome.
• Synonyms: Stüve–Wiedemann/Schwartz–Jampel syndrome type 2; Schwartz–Jampel syndrome type 2; SWS; STWS; congenital bent-bone dysplasia with dysautonomia.
• OMIM: The contemporary systematic review identifies OMIM 601559. One older retrieved review’s abstract instead says 610559, apparently an inconsistency; 601559 should be verified directly against the live OMIM record before ingestion. (warnier2022clinicaloverviewand pages 1-3, mikelonis2014stüvewiedemannsyndromelifr pages 7-8)
• Gene locus: LIFR, chromosome 5p13.1. (bertola2016stüvewiedemannsyndromeupdate pages 5-5, mikelonis2014stüvewiedemannsyndromelifr pages 2-3)
• MONDO, Orphanet, MeSH, ICD-10/ICD-11: exact live identifiers were not independently recoverable from the retrieved primary literature. They should be resolved directly through current ontology releases rather than inferred. ICD coding is likely under a broad osteochondrodysplasia/skeletal-dysplasia category because no disease-specific code was established in this evidence set.

Data provenance

The evidence is aggregated disease-level literature, not individual-level EHR data. Its strongest clinical source is a systematic review of 69 published patients; molecular conclusions derive from family studies, patient cells, and animal models. Individual recent developments are mostly case reports or small case series. (warnier2022clinicaloverviewand pages 1-3, bhalla2024anoveltermination pages 5-6)

2. Etiology, risk, protective factors, and gene–environment interaction

Primary cause

Classic SWS is caused by biallelic germline loss-of-function LIFR variants. In the landmark series, disease was mapped to 5p13.1 in 19 families and 14 distinct variants were found; 12 of 14 predicted premature termination. Null alleles destabilized LIFR transcripts, eliminated functional receptor, and impaired JAK/STAT3 signaling in patient cells. (bertola2016stüvewiedemannsyndromeupdate pages 5-5, bertola2016stüvewiedemannsyndromeupdate pages 5-6)

Genetic risk factors

• Having two pathogenic LIFR alleles is the primary risk factor.
• Consanguinity and known family history substantially increase reproductive risk for this recessive disorder.
• A recurrent LIFR c.653dup frameshift was found in multiple United Arab Emirates families, supporting a regional founder effect. Other reported alleles include c.144_145dup, c.756dup, p.Trp63*, p.Arg418*, and splice variants. (mikelonis2014stüvewiedemannsyndromelifr pages 2-3, bertola2016stüvewiedemannsyndromeupdate pages 5-6)
• Rare non-truncating variants affecting receptor glycosylation may retain partial function and produce an attenuated phenotype, but robust genotype–phenotype rules have not been established. Identical frameshift alleles can yield different severity, implying residual biological, clinical, or modifier effects. (mikelonis2014stüvewiedemannsyndromelifr pages 7-8, bertola2016stüvewiedemannsyndromeupdate pages 5-6)

Environmental and protective factors

No toxin, infection, lifestyle, occupational exposure, diet, age, or sex is known to cause SWS. No validated genetic or environmental protective factor has been identified. Environmental conditions nevertheless influence complications: heat can worsen hyperthermia; impaired swallowing increases aspiration risk; trauma and low bone density increase fracture risk. These modify morbidity, not Mendelian disease occurrence.

No established gene–environment interaction has been demonstrated. Early airway, feeding, temperature, and PAH management may improve survival, but this is clinical risk mitigation rather than etiologic prevention. (warnier2022clinicaloverviewand pages 10-11, mikelonis2014stüvewiedemannsyndromelifr pages 7-8)

3. Phenotypes

Prenatal and neonatal phenotypes

Prenatal ultrasound can show mild-to-moderate micromelia, lower-limb bowing—often tibia more than femur—talipes and camptodactyly. Later findings may include growth restriction and oligohydramnios. In a reviewed UAE series, 8/10 fetuses (80%) later diagnosed with SWS had prenatal skeletal abnormalities, whereas across the broader 69-patient review only 46% had reported antenatal signs. This difference likely reflects referral and family-history effects. (warnier2022clinicaloverviewand pages 1-3, bertola2016stüvewiedemannsyndromeupdate pages 2-3)

Suggested HPO labels include Abnormality of prenatal development, Decreased fetal movement, Short long bones, Bowing of long bones, Micromelia, Talipes, Camptodactyly, Intrauterine growth restriction, and Oligohydramnios.

Core postnatal phenotype

• Skeletal/physical signs: short bowed limbs, progressive bowing, camptodactyly, talipes, restricted elbows/knees, metaphyseal widening, cortical thickening, osteopenia/osteoporosis, fractures, scoliosis or kyphoscoliosis, and femoral-head destruction. Severity is usually marked and orthopedic disease progresses in survivors. Suggested HPO: Bowing of long bones, Cortical thickening of long-bone diaphyses, Metaphyseal widening, Joint contracture, Osteopenia, Osteoporosis, Recurrent fractures, Scoliosis, Kyphosis. (warnier2022clinicaloverviewand pages 1-3, bertola2016stüvewiedemannsyndromeupdate pages 2-3)
• Respiratory/cardiovascular signs: neonatal respiratory distress, recurrent infections often secondary to aspiration, respiratory failure, and PAH. These dominate early mortality. Suggested HPO: Neonatal respiratory distress, Recurrent respiratory infections, Aspiration, Respiratory failure, Pulmonary arterial hypertension. (warnier2022clinicaloverviewand pages 1-3, mikelonis2014stüvewiedemannsyndromelifr pages 7-8)
• Feeding: dysphagia and poor feeding, frequently requiring nasogastric feeding or gastrostomy. Swallowing commonly improves by the second or third year in survivors. Suggested HPO: Dysphagia, Feeding difficulties, Aspiration pneumonia, Failure to thrive. (warnier2022clinicaloverviewand pages 10-11, mikelonis2014stüvewiedemannsyndromelifr pages 7-8)
• Autonomic/neurologic: episodic hyperthermia, paradoxical or excessive sweating, temperature instability, reduced pain perception, absent corneal reflex, reduced patellar reflex, hypotonia and sometimes myotonia. Dysautonomia often becomes less severe with age but may persist. Suggested HPO: Dysautonomia, Hyperthermia, Hyperhidrosis, Reduced pain sensation, Absent corneal reflex, Areflexia, Hypotonia, Myotonia. (warnier2022clinicaloverviewand pages 10-11, oxford2016neuropathiesofstüvewiedemann pages 6-8)
• Ocular/oral: corneal injury/opacification or neurotrophic keratopathy can follow absent corneal sensation; a smooth tongue has been reported. Suggested HPO: Corneal opacity, Neurotrophic keratopathy, Absent corneal reflex, Smooth tongue. (oxford2016neuropathiesofstüvewiedemann pages 6-8, bertola2016stüvewiedemannsyndromeupdate pages 2-3)
• Development: motor development may be delayed because of skeletal disease and hospitalization, but intellectual development is generally normal; all but one published case in one review had normal cognition. Suggested HPO: Delayed gross motor development; avoid annotating intellectual disability as a defining feature. (bertola2016stüvewiedemannsyndromeupdate pages 1-2, warnier2022clinicaloverviewand pages 10-11)

Frequency, severity, and quality of life

The 69-case review found, among children older than 2 years, restricted joint mobility in 81%, spinal deformity in 77%, and fractures in 61%. Daily-life impact includes impaired mobility, recurrent hospitalization, tube feeding, vulnerability to heat, reduced injury awareness, eye-surface damage, orthopedic procedures, and caregiver burden. No validated SWS-specific EQ-5D, SF-36, PROMIS, or disease-specific quality-of-life dataset was identified. (warnier2022clinicaloverviewand pages 1-3)

4. Genetic and molecular information

Causal gene and alleles

• Gene: LIFR, encoding the leukemia inhibitory factor receptor; locus 5p13.1. Retrieved sources describe a 1,097-amino-acid transmembrane cytokine receptor. (mikelonis2014stüvewiedemannsyndromelifr pages 2-3, bertola2016stüvewiedemannsyndromeupdate pages 5-6)
• Variant spectrum: predominantly frameshift, nonsense, and splice-disrupting alleles; occasional missense/non-truncating alleles may impair processing or glycosylation.
• Origin: inherited constitutional/germline, not somatic.
• Functional class: primarily loss of function via nonsense-mediated transcript decay, absent receptor, or severely truncated/nonfunctional protein.
• Classification: well-established null variants in affected recessive families are generally compatible with pathogenic/likely pathogenic ACMG classification, but each submitted allele requires transcript-specific ClinVar/ACMG review. The literature summary cannot replace current variant-level classification.
• Population frequency: no reliable disease-wide allele frequency or carrier frequency was recovered. Causal variants are expected to be rare; the UAE c.653dup founder allele may be locally enriched. (mikelonis2014stüvewiedemannsyndromelifr pages 2-3, bertola2016stüvewiedemannsyndromeupdate pages 5-6)

No confirmed somatic mechanism, pathogenic repeat expansion, mitochondrial variant, aneuploidy, balanced rearrangement, or recurrent large chromosomal abnormality defines classic SWS. Intragenic deletions can be missed by sequence-only assays, so deletion/duplication analysis remains relevant.

Modifier genes and epigenetics

Variable severity among patients carrying the same frameshift suggests modifiers, residual signaling, or care effects, but no modifier gene is validated. Earlier candidate-region suggestions—including OSMR and several neighboring genes—are not established causes of classic SWS. No reproducible disease-specific DNA-methylation signature, histone change, chromatin defect, or epigenetic diagnostic assay was identified. (mikelonis2014stüvewiedemannsyndromelifr pages 7-8, mikelonis2014stüvewiedemannsyndromelifr pages 2-3)

Critical distinction: IL6ST-related extended SWS

A 2020 primary study identified five affected people from three unrelated families with homozygous essential loss-of-function IL6ST variants. Complete GP130 deficiency abolished responses to IL-6, IL-11, IL-27, OSM, and LIF; lentiviral restoration of GP130 rescued signaling. The phenotype included SWS-like skeletal dysplasia and neonatal lung disease plus thrombocytopenia, dermatitis, renal abnormalities, and immune dysfunction. Thus IL6ST belongs on a differential or expanded bent-bone/GP130-signaling panel but is not the canonical cause of SWS1. (chen2020absenceofgp130 pages 8-9, chen2020absenceofgp130 pages 1-1)

5. Environmental information

No environmental, lifestyle, infectious, radiation, pollution, or occupational cause is applicable. Smoking, alcohol, diet, and exercise do not determine disease occurrence. Avoidance of overheating, aspiration, and preventable skeletal injury is clinically important but does not prevent the genotype or congenital phenotype. Vaccination against routine respiratory pathogens is sensible standard care, not SWS-specific immunization.

6. Mechanism and pathophysiology

Causal chain

1. Upstream lesion: biallelic LIFR loss-of-function variants destabilize mRNA or prevent production/trafficking of functional LIFR.
2. Receptor defect: LIFR cannot form effective signaling complexes with GP130 for relevant IL-6-family ligands, including LIF, cardiotrophin-1, oncostatin M, CNTF-associated complexes, and CLCF1-associated signaling.
3. Signal failure: ligand-induced JAK activation and STAT3 phosphorylation are impaired; MAPK and PI3K signaling may also be reduced.
4. Developmental consequences: disturbed bone formation/remodeling, osteoclast imbalance, motor/autonomic neuronal dysfunction, and impaired neuromuscular/respiratory homeostasis.
5. Clinical output: congenital bowing and contractures; osteopenia/fractures; impaired swallowing and respiration; abnormal sweating, thermoregulation, nociception, and reflexes. (bertola2016stüvewiedemannsyndromeupdate pages 5-5, bertola2016stüvewiedemannsyndromeupdate pages 5-6, oxford2016neuropathiesofstüvewiedemann pages 5-6)

Suggested GO biological-process terms are cytokine-mediated signaling pathway, JAK–STAT cascade, STAT protein phosphorylation, skeletal system development, bone remodeling, osteoclast differentiation, motor-neuron development, autonomic nervous system development, and regulation of body temperature. Suggested cell types are osteoblast, osteoclast, chondrocyte, motor neuron, sensory neuron, sympathetic neuron, skeletal myocyte, and pulmonary vascular cells. These ontology labels should be assigned only at evidence-appropriate granularity.

Protein, cellular, metabolic, and immune effects

The primary biochemical abnormality is cytokine-receptor dysfunction, not an enzyme deficiency or ion-channel defect. Lifr-null mice show reduced fetal bone volume, increased osteoclasts, neural defects, and perinatal death, supporting effects on skeletal and nervous-system development. (bertola2016stüvewiedemannsyndromeupdate pages 5-5, mikelonis2014stüvewiedemannsyndromelifr pages 2-3)

Classic LIFR-SWS is not primarily an immunodeficiency. Recurrent respiratory infections are often attributed to dysphagia and aspiration, although JAK/STAT impairment could contribute. Broad immunodeficiency is much more characteristic of complete IL6ST/GP130 deficiency and should prompt reconsideration of the molecular diagnosis. (chen2020absenceofgp130 pages 1-1, warnier2022clinicaloverviewand pages 11-12)

No validated SWS-specific transcriptomic, proteomic, metabolomic, lipidomic, single-cell, spatial-transcriptomic, or multi-omic signature was identified. Functional patient-cell assays measuring ligand-induced pSTAT3 are research tools, not routine diagnostics. Recent structural work on GP130-family complexes improves receptor-level understanding, but it has not yet produced an SWS therapy.

7. Anatomical structures affected

• Primary organs/systems: skeleton—especially femora, tibiae, spine, hips, hands and feet; peripheral autonomic, sensory and motor nervous systems; respiratory tract and lungs; swallowing apparatus; and cornea.
• Secondary involvement: pulmonary vasculature in PAH; recurrent lung injury from aspiration; osteoporosis and progressive vertebral/hip damage.
• Suggested UBERON labels: long bone, femur, tibia, vertebral column, hip joint, lung, pulmonary artery, pharynx, esophagus, cornea, peripheral nervous system and autonomic nervous system.
• Suggested Cell Ontology labels: chondrocyte, osteoblast, osteoclast, motor neuron, sensory neuron, sympathetic neuron, corneal epithelial cell and pulmonary arterial smooth-muscle cell.
• Subcellular level: plasma-membrane receptor complex and cytoplasmic JAK/STAT machinery; suggested GO cellular components include plasma membrane, receptor complex, cytoplasm, and nucleus.
• Long-bone and ocular findings are generally bilateral/systemic rather than characteristically unilateral. (oxford2016neuropathiesofstüvewiedemann pages 6-8, bertola2016stüvewiedemannsyndromeupdate pages 5-5, warnier2022clinicaloverviewand pages 1-3)

8. Temporal development and natural history

Onset is congenital, with an antenatal skeletal phenotype in a subset and acute neonatal respiratory, feeding, and thermoregulatory disease. The critical period is birth through age 2, when respiratory failure, aspiration, hyperthermic crises, and PAH drive mortality. Dysphagia often improves by ages 2–3 and temperature crises tend to become less frequent, but skeletal disease remains chronic and progressive. (warnier2022clinicaloverviewand pages 1-3, warnier2022clinicaloverviewand pages 10-11)

A practical, nonvalidated staging scheme is:

1. Prenatal: short/bowed long bones, reduced movement or contractures; sometimes late growth restriction.
2. Neonatal–2 years: highest-risk dysautonomic/respiratory phase.
3. Childhood survivor phase: improving swallowing and autonomic stability, accumulating fractures, contractures and spinal/hip deformity.
4. Adolescent/adult phase: lifelong orthopedic disability and residual autonomic/ocular risk; rare long-term survivors are documented.

There is no true remission of the genetic disorder. Apparent improvement reflects maturation and survival of the early autonomic phase, not molecular correction. (bertola2016stüvewiedemannsyndromeupdate pages 2-2, warnier2022clinicaloverviewand pages 10-11)

9. Inheritance and population

Inheritance is autosomal recessive. For two confirmed carriers, each pregnancy has an expected 25% affected, 50% carrier, and 25% non-carrier/non-affected probability. Penetrance of two severe null alleles appears high, but expressivity and survival are variable. No anticipation is expected. Germline mosaicism is not established as a major mechanism, although standard residual recurrence counseling applies when parental testing is incomplete.

General-population prevalence and incidence are unknown. One review cited approximately 0.52 per 10,000 births in highly inbred populations, which must not be generalized globally. Cases have been reported in Europe, Africa, the Americas, and the Middle East. Both sexes are affected; no validated sex bias exists. Consanguinity and the UAE founder allele explain regional enrichment. (bertola2016stüvewiedemannsyndromeupdate pages 2-2, mikelonis2014stüvewiedemannsyndromelifr pages 2-3)

No robust global carrier frequency, ethnicity-stratified incidence, or national registry estimate was found.

10. Diagnostics

Clinical and imaging diagnosis

Suspect SWS in a fetus or neonate with short, bowed long bones plus contractures and disproportionate dysautonomia, respiratory distress, dysphagia, unexplained hyperthermia or abnormal sweating. A skeletal survey may show bowed femora/tibiae, diaphyseal cortical thickening, widened metaphyses, abnormal trabeculation and reduced density. Echocardiography is important because PAH is a major prognostic marker. Swallow assessment, respiratory evaluation, nutritional assessment, ophthalmologic examination, and bone-density/orthopedic surveillance define complications. (warnier2022clinicaloverviewand pages 1-3, bertola2016stüvewiedemannsyndromeupdate pages 2-3)

There is no validated biochemical biomarker, enzyme assay, characteristic metabolite, pathology stain, EEG/EMG signature, or circulating marker. Laboratory investigations should evaluate complications—blood gases, infection, electrolytes, calcium/vitamin D status, rhabdomyolysis when suspected, and adrenal function if clinically indicated—rather than confirm SWS.

Molecular strategy

1. First line: sequence LIFR with deletion/duplication analysis if phenotype is classic and family history is informative.
2. Panel: bent-bone/skeletal-dysplasia or dysautonomia panel including LIFR; include IL6ST, SOX9, SLC26A2 and other phenotype-driven differentials.
3. WES/WGS: appropriate for atypical or panel-negative disease, consanguineous families, or suspected structural/noncoding alleles. WGS offers better structural and deep-intronic coverage.
4. CMA/karyotype/FISH: not first-line for a classic recessive single-gene phenotype, but CMA is reasonable if congenital anomalies or developmental findings suggest a copy-number disorder.
5. Mitochondrial and repeat-expansion testing are not routinely indicated.

RNA studies can clarify splice variants, while patient-cell pSTAT3 assays can establish functional consequences in research or specialized diagnostic settings. (chen2020absenceofgp130 pages 8-9, bertola2016stüvewiedemannsyndromeupdate pages 5-6)

Differential diagnosis

Important differentials include campomelic dysplasia, kyphomelic dysplasia, diastrophic dysplasia, osteogenesis imperfecta/severe bone-fragility disorders, and other congenital bowing or arthrogryposis syndromes. Campomelic dysplasia is suggested by SOX9-related scapular/pelvic abnormalities, 11 rib pairs, sex-development differences, and characteristic craniofacial findings. SWS is distinguished by its marked dysautonomia, episodic hyperthermia, sweating disturbance, reduced pain sensation, and LIFR genotype. (bertola2016stüvewiedemannsyndromeupdate pages 2-2)

Screening

SWS is not part of routine biochemical newborn screening. Targeted carrier/cascade testing is appropriate for relatives after familial variants are known. Prenatal diagnosis may use chorionic-villus sampling or amniocentesis for the familial alleles; ultrasound alone is insufficiently sensitive because only 46% of cases in the systematic review had reported antenatal signs. (warnier2022clinicaloverviewand pages 1-3, bertola2016stüvewiedemannsyndromeupdate pages 2-2)

11. Outcomes and prognosis

The systematic-review abstract states: “Mortality rate is higher during the first 2 years (42% <2 years; 10% >2 years) mainly due to respiratory failure,” and identifies PAH as a poor prognostic factor with 63% mortality. These are the most defensible quantitative estimates, but not population survival rates. Five- and ten-year survival and life expectancy are unknown. (warnier2022clinicaloverviewand pages 1-3)

Poor prognostic factors include neonatal respiratory failure, recurrent aspiration/infection, severe dysphagia, frequent hyperthermic crises, and especially PAH. Surviving beyond age 2 is favorable for near-term survival, but fractures, spinal deformity, restricted mobility, chronic pain or unrecognized injury, and ocular damage cause lifelong morbidity. Cognitive prognosis is usually favorable. No validated molecular prognostic biomarker exists. (warnier2022clinicaloverviewand pages 10-11, warnier2022clinicaloverviewand pages 1-3)

12. Treatment and current applications

Standard care

No curative, FDA/EMA-approved disease-modifying, genotype-guided, gene, cell, RNA, or immunotherapy exists. Management is supportive and coordinated through pediatrics, pulmonology, cardiology, clinical genetics, nutrition/gastroenterology, orthopedics, rehabilitation, ophthalmology, dentistry and anesthesia. (warnier2022clinicaloverviewand pages 10-11, bhalla2024anoveltermination pages 5-6)

• Airway/feeding: aspiration precautions; swallow evaluation; thickened or modified feeds where safe; nasogastric feeding in the short term and gastrostomy when prolonged enteral support is needed. Respiratory support and prompt treatment of infections are central. Suggested NCIT concepts: Supportive Care, Nasogastric Intubation, Gastrostomy, Respiratory Therapy. (mikelonis2014stüvewiedemannsyndromelifr pages 7-8, bhalla2024anoveltermination pages 5-6)
• Thermoregulation: cooling plans and hydration, with antipyretic/comfort measures. A 2024 case described escalation using acetaminophen, ibuprofen and bromocriptine; this is case-level practice, not trial-validated therapy, and autonomic hyperthermia may not respond like infectious fever. Suggested CHEBI/NCIT entities: acetaminophen, ibuprofen, bromocriptine. (bhalla2024anoveltermination pages 5-6)
• Cardiopulmonary: screen for and manage PAH with specialist protocols; no SWS-specific PAH regimen has been tested.
• Bone/orthopedic: physiotherapy, positioning, braces, calcium/vitamin-D sufficiency, consideration of bisphosphonates for bone fragility, fracture treatment, and correction of severe limb/spinal deformity. Telescopic intramedullary rods may reduce recurrent deformity compared with fixed rods. Suggested NCIT concepts: Physical Therapy, Orthotic Device, Bisphosphonate Therapy, Intramedullary Rod Placement. (warnier2022clinicaloverviewand pages 10-11)
• Eyes: frequent corneal surveillance, lubrication and protection because absent corneal sensation can allow silent injury. Contemporary case literature has explored surgical management of neurotrophic keratopathy, but comparative outcomes are unavailable.
• Safety/rehabilitation: daily skin and limb checks for painless injury; physical and occupational therapy; mobility aids; home temperature planning; dental surveillance.

Anesthesia

Malignant-hyperthermia concern has historically complicated planning, but the 2024 review notes multiple reported anesthetics without malignant hyperthermia. This absence of reported events does not prove no risk; preoperative pulmonary, PAH, airway, aspiration and temperature assessment remains essential. (bhalla2024anoveltermination pages 5-6)

Experimental approaches

Gentamicin produced experimental premature-stop-codon readthrough and has been proposed only for selected nonsense alleles. Nephrotoxicity, ototoxicity, uncertain tissue exposure and lack of clinical efficacy data prevent routine use. Antisense exon skipping and CRISPR correction remain conceptual/preclinical. No relevant disease-specific interventional ClinicalTrials.gov study was found by the tool search. (bertola2016stüvewiedemannsyndromeupdate pages 2-2, oxford2016neuropathiesofstüvewiedemann pages 6-8)

13. Prevention

Because SWS is a congenital Mendelian disorder, diet, lifestyle, vaccination, or exposure avoidance cannot provide primary prevention. Effective reproductive prevention options are:

• preconception genetic counseling;
• cascade carrier testing after identification of familial LIFR variants;
• partner testing in high-risk or founder populations;
• preimplantation genetic testing for monogenic disease;
• prenatal molecular diagnosis by CVS or amniocentesis;
• detailed fetal ultrasonography, recognizing incomplete sensitivity.

Secondary/tertiary prevention consists of early molecular diagnosis, aspiration prevention, PAH screening, thermoregulation plans, corneal protection, fracture prevention and multidisciplinary surveillance. Routine immunization is appropriate to reduce preventable respiratory disease but is not disease-specific prophylaxis. (warnier2022clinicaloverviewand pages 10-11, bertola2016stüvewiedemannsyndromeupdate pages 2-2)

14. Other species and natural disease

No well-established naturally occurring veterinary homolog of human LIFR-related SWS was identified; zoonotic transmission is not applicable. Orthologous LIFR genes are evolutionarily conserved across vertebrates, but the evidence base concerns experimentally engineered rather than naturally diseased animals. Suggested taxonomy for the main experimental model is Mus musculus (NCBI Taxonomy 10090). Breed-specific VBO annotation is not applicable.

15. Model organisms and advanced research

The principal model is the Lifr-null mouse. Homozygous knockout causes placental, skeletal, neural and metabolic abnormalities with perinatal lethality. Reported disease-relevant findings include reduced fetal bone volume, increased osteoclasts and reduced astrocytic/neural populations. This recapitulates developmental skeletal and neurologic severity and supports LIFR causality. Its limitations are perinatal death, incomplete modeling of long-term human survivor phenotypes, and species differences in placentation and cytokine redundancy. (bertola2016stüvewiedemannsyndromeupdate pages 5-5, mikelonis2014stüvewiedemannsyndromelifr pages 2-3)

Patient-derived fibroblasts or lymphoblastoid cells are useful for receptor expression and ligand-induced pSTAT3 assays. In the related IL6ST disorder, transfection and lentiviral rescue experiments directly restored GP130 signaling, providing proof that receptor replacement can correct the cellular defect, although this is not yet a therapy. (chen2020absenceofgp130 pages 8-9, chen2020absenceofgp130 pages 1-1)

Recent developments, 2023–2024

1. Longer survival is increasingly recognized. A 2024 report described a 5-year-old survivor and emphasized structured home hyperthermia and respiratory plans rather than assuming universal infant lethality. The abstract summarizes SWS as characterized by “bowing of long bones, dysautonomia, temperature dysregulation, swallowing and feeding difficulties, and frequent respiratory infections.” Published April 2024; DOI: https://doi.org/10.3389/fped.2024.1341841. (bhalla2024anoveltermination pages 5-6)
2. Survivor-focused care expanded in 2023 literature, including a UK pediatric survivor series referenced in the 2024 report. Evidence remains small-series level and does not supersede the 69-case systematic review. (bhalla2024anoveltermination pages 6-6)
3. Ophthalmic implementation: 2023–2024 reports described surgical treatment of neurotrophic corneal disease, including tarsoconjunctival approaches and corneal neurotization. These are individualized procedures without controlled comparative evidence.
4. Structural cytokine-receptor biology advanced. Cryo-EM studies of GP130-family ligand–receptor complexes clarified how LIF, CLCF1 and related cytokines assemble signaling complexes. This improves mechanistic interpretation but has not yielded an SWS-targeted drug.
5. Variant discovery continues, but most 2023–2024 reports are single cases. Current expert interpretation remains that prompt recognition and multidisciplinary supportive care offer the clearest near-term benefit; disease-modifying receptor restoration remains an unmet research need. (bhalla2024anoveltermination pages 5-6)

Evidence limitations and knowledge gaps

There are no population registries large enough to provide reliable incidence, sex ratio, carrier frequency, five- or ten-year survival, or treatment-response rates. Phenotype frequencies derive from reported cases and likely overrepresent severe and unusual presentations. No controlled therapeutic trial, validated clinical guideline, SWS-specific quality-of-life measure, prognostic molecular biomarker, modifier gene, protective allele, epigenetic signature, or diagnostic multi-omics profile was identified. Exact MONDO, Orphanet, MeSH and ICD identifiers require direct validation against live databases. PMID values were not consistently exposed in the retrieved full texts; therefore DOI URLs and publication dates are supplied rather than inventing identifiers.

Key source list

• Warnier H, et al. Clinical overview and outcome of the Stuve-Wiedemann syndrome: a systematic review. Orphanet Journal of Rare Diseases. Published April 2022. https://doi.org/10.1186/s13023-022-02323-8. (warnier2022clinicaloverviewand pages 1-3)
• Dagoneau N, et al. Null leukemia inhibitory factor receptor mutations in Stuve-Wiedemann/Schwartz-Jampel type 2 syndrome. American Journal of Human Genetics. Published February 2004. https://doi.org/10.1086/381715. The retrieved evidence reports 19 families, 14 variants, and functional loss of LIFR/JAK–STAT3 signaling. (bertola2016stüvewiedemannsyndromeupdate pages 5-5, bertola2016stüvewiedemannsyndromeupdate pages 5-6)
• Mikelonis D, et al. Stüve-Wiedemann syndrome: LIFR and associated cytokines in clinical course and etiology. Orphanet Journal of Rare Diseases. Published March 2014. https://doi.org/10.1186/1750-1172-9-34. (mikelonis2014stüvewiedemannsyndromelifr pages 7-8, mikelonis2014stüvewiedemannsyndromelifr pages 2-3)
• Bertola DR, et al. Stüve-Wiedemann Syndrome: Update on Clinical and Genetic Aspects. Molecular Syndromology. Published March 2016. https://doi.org/10.1159/000444729. (bertola2016stüvewiedemannsyndromeupdate pages 1-2, bertola2016stüvewiedemannsyndromeupdate pages 2-3)
• Chen Y-H, et al. Absence of GP130 cytokine receptor signaling causes extended Stüve-Wiedemann syndrome. Journal of Experimental Medicine. Published January 2020. https://doi.org/10.1084/jem.20191306. (chen2020absenceofgp130 pages 8-9, chen2020absenceofgp130 pages 1-1)
• Bhalla DM, et al. A novel termination site in a case of Stüve–Wiedemann syndrome: case report and review of literature. Frontiers in Pediatrics. Published April 2024. https://doi.org/10.3389/fped.2024.1341841. (bhalla2024anoveltermination pages 5-6)

References

1. (warnier2022clinicaloverviewand pages 1-3): Hélène Warnier, Christophe Barrea, Sarah Bethlen, Isabelle Schrouff, and Julie Harvengt. Clinical overview and outcome of the stuve-wiedemann syndrome: a systematic review. Orphanet Journal of Rare Diseases, Apr 2022. URL: https://doi.org/10.1186/s13023-022-02323-8, doi:10.1186/s13023-022-02323-8. This article has 22 citations and is from a peer-reviewed journal.

2. (warnier2022clinicaloverviewand pages 10-11): Hélène Warnier, Christophe Barrea, Sarah Bethlen, Isabelle Schrouff, and Julie Harvengt. Clinical overview and outcome of the stuve-wiedemann syndrome: a systematic review. Orphanet Journal of Rare Diseases, Apr 2022. URL: https://doi.org/10.1186/s13023-022-02323-8, doi:10.1186/s13023-022-02323-8. This article has 22 citations and is from a peer-reviewed journal.

3. (chen2020absenceofgp130 pages 8-9): Yin-Huai Chen, Giedre Grigelioniene, Phillip T. Newton, Jacob Gullander, Maria Elfving, Anna Hammarsjö, Dominyka Batkovskyte, Hessa S. Alsaif, Wesam I.Y. Kurdi, Firdous Abdulwahab, Veerabahu Shanmugasundaram, Luke Devey, Séverine Bacrot, Jana Brodszki, Celine Huber, Ben Hamel, David Gisselsson, Nikos Papadogiannakis, Katarina Jedrycha, Barbara Gürtl-Lackner, Andrei S. Chagin, Gen Nishimura, Dominik Aschenbrenner, Fowzan S. Alkuraya, Arian Laurence, Valérie Cormier-Daire, and Holm H. Uhlig. Absence of gp130 cytokine receptor signaling causes extended stüve-wiedemann syndrome. The Journal of Experimental Medicine, Jan 2020. URL: https://doi.org/10.1084/jem.20191306, doi:10.1084/jem.20191306. This article has 75 citations.

4. (chen2020absenceofgp130 pages 1-1): Yin-Huai Chen, Giedre Grigelioniene, Phillip T. Newton, Jacob Gullander, Maria Elfving, Anna Hammarsjö, Dominyka Batkovskyte, Hessa S. Alsaif, Wesam I.Y. Kurdi, Firdous Abdulwahab, Veerabahu Shanmugasundaram, Luke Devey, Séverine Bacrot, Jana Brodszki, Celine Huber, Ben Hamel, David Gisselsson, Nikos Papadogiannakis, Katarina Jedrycha, Barbara Gürtl-Lackner, Andrei S. Chagin, Gen Nishimura, Dominik Aschenbrenner, Fowzan S. Alkuraya, Arian Laurence, Valérie Cormier-Daire, and Holm H. Uhlig. Absence of gp130 cytokine receptor signaling causes extended stüve-wiedemann syndrome. The Journal of Experimental Medicine, Jan 2020. URL: https://doi.org/10.1084/jem.20191306, doi:10.1084/jem.20191306. This article has 75 citations.

5. (mikelonis2014stüvewiedemannsyndromelifr pages 7-8): Dawn Mikelonis, Cheryl L Jorcyk, Ken Tawara, and Julia Thom Oxford. Stüve-wiedemann syndrome: lifr and associated cytokines in clinical course and etiology. Orphanet Journal of Rare Diseases, 9:34-34, Mar 2014. URL: https://doi.org/10.1186/1750-1172-9-34, doi:10.1186/1750-1172-9-34. This article has 47 citations and is from a peer-reviewed journal.

6. (bertola2016stüvewiedemannsyndromeupdate pages 1-2): Débora Romeo Bertola, Rachel S. Honjo, and Wagner A.R. Baratela. Stüve-wiedemann syndrome: update on clinical and genetic aspects. Molecular Syndromology, 7:12-18, Mar 2016. URL: https://doi.org/10.1159/000444729, doi:10.1159/000444729. This article has 38 citations and is from a peer-reviewed journal.

7. (bertola2016stüvewiedemannsyndromeupdate pages 5-5): Débora Romeo Bertola, Rachel S. Honjo, and Wagner A.R. Baratela. Stüve-wiedemann syndrome: update on clinical and genetic aspects. Molecular Syndromology, 7:12-18, Mar 2016. URL: https://doi.org/10.1159/000444729, doi:10.1159/000444729. This article has 38 citations and is from a peer-reviewed journal.

8. (mikelonis2014stüvewiedemannsyndromelifr pages 2-3): Dawn Mikelonis, Cheryl L Jorcyk, Ken Tawara, and Julia Thom Oxford. Stüve-wiedemann syndrome: lifr and associated cytokines in clinical course and etiology. Orphanet Journal of Rare Diseases, 9:34-34, Mar 2014. URL: https://doi.org/10.1186/1750-1172-9-34, doi:10.1186/1750-1172-9-34. This article has 47 citations and is from a peer-reviewed journal.

9. (bertola2016stüvewiedemannsyndromeupdate pages 5-6): Débora Romeo Bertola, Rachel S. Honjo, and Wagner A.R. Baratela. Stüve-wiedemann syndrome: update on clinical and genetic aspects. Molecular Syndromology, 7:12-18, Mar 2016. URL: https://doi.org/10.1159/000444729, doi:10.1159/000444729. This article has 38 citations and is from a peer-reviewed journal.

10. (bertola2016stüvewiedemannsyndromeupdate pages 2-2): Débora Romeo Bertola, Rachel S. Honjo, and Wagner A.R. Baratela. Stüve-wiedemann syndrome: update on clinical and genetic aspects. Molecular Syndromology, 7:12-18, Mar 2016. URL: https://doi.org/10.1159/000444729, doi:10.1159/000444729. This article has 38 citations and is from a peer-reviewed journal.

11. (bertola2016stüvewiedemannsyndromeupdate pages 2-3): Débora Romeo Bertola, Rachel S. Honjo, and Wagner A.R. Baratela. Stüve-wiedemann syndrome: update on clinical and genetic aspects. Molecular Syndromology, 7:12-18, Mar 2016. URL: https://doi.org/10.1159/000444729, doi:10.1159/000444729. This article has 38 citations and is from a peer-reviewed journal.

12. (oxford2016neuropathiesofstüvewiedemann pages 6-8): Alexandra E Oxford, C. Jorcyk, and J. Oxford. Neuropathies of stüve-wiedemann syndrome due to mutations in leukemia inhibitory factor receptor (lifr) gene. Journal of neurology & neuromedicine, 1 7:37-44, Oct 2016. URL: https://doi.org/10.29245/2572.942x/2016/7.1068, doi:10.29245/2572.942x/2016/7.1068. This article has 8 citations.

13. (oxford2016neuropathiesofstüvewiedemann pages 5-6): Alexandra E Oxford, C. Jorcyk, and J. Oxford. Neuropathies of stüve-wiedemann syndrome due to mutations in leukemia inhibitory factor receptor (lifr) gene. Journal of neurology & neuromedicine, 1 7:37-44, Oct 2016. URL: https://doi.org/10.29245/2572.942x/2016/7.1068, doi:10.29245/2572.942x/2016/7.1068. This article has 8 citations.

14. (chen2020absenceofgp130 pages 1-2): Yin-Huai Chen, Giedre Grigelioniene, Phillip T. Newton, Jacob Gullander, Maria Elfving, Anna Hammarsjö, Dominyka Batkovskyte, Hessa S. Alsaif, Wesam I.Y. Kurdi, Firdous Abdulwahab, Veerabahu Shanmugasundaram, Luke Devey, Séverine Bacrot, Jana Brodszki, Celine Huber, Ben Hamel, David Gisselsson, Nikos Papadogiannakis, Katarina Jedrycha, Barbara Gürtl-Lackner, Andrei S. Chagin, Gen Nishimura, Dominik Aschenbrenner, Fowzan S. Alkuraya, Arian Laurence, Valérie Cormier-Daire, and Holm H. Uhlig. Absence of gp130 cytokine receptor signaling causes extended stüve-wiedemann syndrome. The Journal of Experimental Medicine, Jan 2020. URL: https://doi.org/10.1084/jem.20191306, doi:10.1084/jem.20191306. This article has 75 citations.

15. (bhalla2024anoveltermination pages 5-6): Deepali M. Bhalla, Sunil K Sati, Donald Basel, and Vijender Karody. A novel termination site in a case of stüve–wiedemann syndrome: case report and review of literature. Frontiers in Pediatrics, Apr 2024. URL: https://doi.org/10.3389/fped.2024.1341841, doi:10.3389/fped.2024.1341841. This article has 2 citations.

16. (warnier2022clinicaloverviewand pages 11-12): Hélène Warnier, Christophe Barrea, Sarah Bethlen, Isabelle Schrouff, and Julie Harvengt. Clinical overview and outcome of the stuve-wiedemann syndrome: a systematic review. Orphanet Journal of Rare Diseases, Apr 2022. URL: https://doi.org/10.1186/s13023-022-02323-8, doi:10.1186/s13023-022-02323-8. This article has 22 citations and is from a peer-reviewed journal.

17. (bhalla2024anoveltermination pages 6-6): Deepali M. Bhalla, Sunil K Sati, Donald Basel, and Vijender Karody. A novel termination site in a case of stüve–wiedemann syndrome: case report and review of literature. Frontiers in Pediatrics, Apr 2024. URL: https://doi.org/10.3389/fped.2024.1341841, doi:10.3389/fped.2024.1341841. This article has 2 citations.

Artifacts

• Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.